pandem
influenza
viru
caus
first
influenza
pandem
centuri
lead
disproportion
fatal
lowrisk
popul
despit
gener
mild
natur
ill
advanc
scienc
technolog
allow
detail
studi
pathogenesi
novel
viru
mani
alreadi
publish
less
year
start
pandem
inform
gener
cell
line
anim
model
clinic
data
analysi
provid
us
greater
understand
behavior
viru
associ
host
respons
new
knowledg
allow
us
formul
scientif
sound
evidencebas
manag
plan
emerg
human
case
influenza
viru
infect
sever
acut
respiratori
syndrom
sar
coronaviru
infect
alert
world
devast
consequ
novel
human
respiratori
virus
anticip
pandem
influenza
may
caus
even
greater
morbid
mortal
worldwid
antivir
stockpil
clinic
trial
vaccin
start
mani
develop
countri
expect
current
pandem
influenza
viru
first
detect
march
spread
worldwid
although
patient
infect
novel
strain
present
mild
upper
respiratori
tract
symptom
higher
fatal
rate
children
young
adult
clearli
differenti
viru
season
influenza
viru
moreov
obes
patient
pregnant
postpartum
women
increas
risk
complic
requir
intens
care
even
death
distinct
clinic
observ
pose
import
scientif
question
understand
differ
pathogenesi
pandem
viru
season
influenza
viru
mark
advanc
scienc
technolog
sinc
last
pandem
allow
unpreced
opportun
detail
studi
pathogenesi
infect
result
studi
import
potenti
implic
treatment
viru
review
discuss
paper
contrast
season
influenza
viru
viru
greater
predilect
lower
respiratori
tract
demonstr
studi
ferret
mice
fact
patient
may
viru
detect
exclus
lower
respiratori
tract
specimen
may
partial
explain
broader
receptor
bind
properti
bind
influenza
viru
host
cell
surfac
glycoprotein
glycolipid
mediat
viral
hemagglutinin
ha
amino
acid
substitut
ha
could
affect
bind
viru
number
ha
alter
bind
specif
avian
type
receptor
subtyp
avian
human
adapt
achiev
substitut
posit
construct
theoret
haglycan
structur
complex
found
uniqu
viru
togeth
may
form
posit
charg
lysin
fenc
base
bind
site
favor
bind
glycan
addit
residu
critic
bind
glycan
viru
postul
stabil
uniqu
set
residu
human
season
influenza
viru
substitut
reduc
bind
glycan
viru
interact
rescu
lysin
fenc
predict
confirm
carbohydr
microarray
analysi
show
viru
could
also
bind
sialic
acid
residu
similar
viru
howev
direct
glycan
bind
assay
anoth
research
group
show
ha
viru
could
bind
sialic
acid
residu
minim
sialic
acid
residu
appar
contradict
may
relat
select
differ
sialyl
probe
differ
bind
assay
abil
bind
glycan
import
sinc
may
associ
bind
lower
respiratori
tract
human
vitro
studi
show
viru
could
replic
human
cell
line
origin
extrapulmonari
tissu
includ
gastrointestin
genitourinari
neuromuscular
immun
cell
conjunctiva
viral
load
greatest
colorect
adenocarcinoma
rhabdomyosarcoma
rd
cell
line
consist
clinic
observ
gastrointestin
symptom
rhabdomyolysi
howev
level
viral
replic
cell
line
similar
season
viru
except
human
conjunctiva
viru
better
replic
broad
viral
tropism
cell
line
accord
detect
viru
extrapulmonari
specimen
includ
blood
urin
stool
patient
infect
viru
sinc
receptor
bind
critic
pathogenesi
influenza
viru
infect
mutat
bind
site
ha
may
alter
virul
number
substitut
ha
viru
found
common
among
fatal
human
case
strain
carri
substitut
ha
also
found
unit
state
spain
itali
clinic
data
case
avail
analysi
use
inform
spectrum
method
bioinformat
platform
found
posit
may
associ
chang
bind
specif
howev
bind
properti
mutant
viru
determin
studi
requir
verifi
clinic
signific
substitut
sever
diseas
attribut
specif
virul
factor
viru
may
lead
excess
inflamm
case
virus
known
virul
factor
viru
includ
increas
viral
replic
substitut
protein
induc
apoptosi
enhanc
inflamm
mice
predispos
secondari
bacteri
infect
antagon
antivir
effect
interferon
multibas
ha
cleavag
sequenc
allow
cleavag
ubiquit
proteas
viru
fulllength
postul
import
virul
factor
howev
virul
factor
absent
viru
glutam
acid
found
residu
truncat
due
presenc
stop
codon
posit
delet
pdz
ligand
domain
found
singl
basic
amino
acid
found
ha
cleavag
site
even
introduct
known
virulencedetermin
mutat
viru
enhanc
virul
howev
sequenc
analysi
viru
gene
identifi
rare
season
influenza
studi
demonstr
pair
substitut
associ
increas
polymeras
activ
enhanc
viral
replic
level
viral
load
pathophysiolog
focu
infect
repres
dynam
interact
viru
host
immun
level
result
viral
replic
destruct
host
immun
respons
may
import
determin
diseas
sever
higher
viral
load
respiratori
tract
sampl
associ
fatal
diseas
diseas
sever
infect
due
respiratori
syncyti
viru
human
metapneumoviru
howev
compar
season
influenza
viru
infect
nasopharyng
viral
load
slightli
lower
patient
viru
infect
sever
case
viru
infect
initi
viral
load
found
similar
patient
mild
diseas
slower
declin
viral
load
therefor
tempor
rate
clearanc
viru
rather
initi
viral
load
import
determin
sever
accord
studi
conduct
mice
show
effect
host
innat
immun
respons
occur
h
infect
time
viral
load
start
decreas
reassort
triplereassort
swine
influenza
viru
contain
gene
origin
avian
viru
season
human
viru
classic
swine
viru
eurasian
avianlik
swine
influenza
viru
origin
avian
viru
result
viru
antigen
distinct
recent
season
influenza
virus
serolog
survey
conduct
worldwid
determin
level
preexist
immun
popul
unit
state
patient
born
born
microneutr
studi
determin
microneutr
titer
correspond
hemagglutin
inhibit
titer
hai
associ
reduct
risk
infect
england
level
crossreact
antibodi
increas
significantli
age
year
old
hai
similar
find
report
finland
peopl
born
hai
present
born
born
level
preexist
crossreact
antibodi
much
lower
studi
conduct
asia
serolog
survey
perform
guangxi
china
serum
sampl
hai
none
year
old
vaccin
studi
show
particip
age
year
hai
vaccin
japan
preexist
neutral
antibodi
present
born
preval
studi
show
level
crossreact
antibodi
tend
higher
older
popul
higher
rate
crossreact
antibodi
older
popul
propos
due
cross
reactiv
gener
exposur
viru
immedi
descend
monoclon
antibodi
gener
ha
site
sa
viru
neutral
activ
viru
reduc
replic
viru
lung
mice
furthermor
antibodi
gener
swine
origin
viru
vaccin
also
protect
mice
infect
viru
lack
exposur
virus
may
partial
explain
younger
adult
higher
clinic
attack
rate
seriou
diseas
influenza
season
influenza
despit
fact
sever
diseas
disproportion
affect
young
adult
still
infect
patient
age
group
mild
diseas
antibodi
level
fulli
explain
situat
protect
immun
depend
level
antibodi
also
cell
immun
found
cell
epitop
cell
epitop
conserv
viru
compar
season
influenza
viru
furthermor
memori
cell
respons
measur
interferong
secret
stimul
cell
epitop
present
conserv
nonconserv
epitop
similarli
studi
use
blood
sampl
donor
histori
viru
infect
show
viru
peptid
could
induc
specif
cell
respons
result
consist
previou
studi
human
volunt
demonstr
import
cell
immun
absenc
cross
reactiv
antibodi
studi
highlight
role
cell
immun
especi
patient
without
protect
antibodi
cellmedi
immun
respons
cytotox
lymphocyt
recruit
earli
enough
viral
load
control
lower
level
earli
stage
diseas
viral
load
may
drop
faster
would
result
less
cell
death
cytokin
activ
addit
cell
natur
killer
nk
cell
also
involv
defens
influenza
major
nk
activ
receptor
involv
nk
cell
cytotox
abl
recogn
ha
viru
subsequ
direct
kill
contrast
viru
could
elicit
direct
kill
viru
may
one
reason
viru
pathogen
influenza
viru
human
hypercytokinemia
associ
diseas
sever
sever
respiratori
virus
includ
sar
coronaviru
viru
vitro
studi
human
macrophag
infect
viru
show
induc
proinflammatori
cytokin
level
similar
cell
infect
season
influenza
viru
much
lower
viru
weaker
induct
interferon
found
dendrit
cell
infect
viru
season
influenza
viru
infect
mous
adapt
virus
anoth
studi
show
compar
cytokin
respons
bronchial
epitheli
cell
alveolar
type
ilik
pneumocyt
infect
viru
season
viru
macaqu
model
viru
infect
persist
elev
level
monocyt
chemoattract
macrophag
inflammatori
protein
alpha
inflammatori
lung
ifng
overexpress
lung
mous
model
coinfect
influenza
viru
staphylococcu
aureu
lung
tissu
fatal
human
case
patient
viru
infect
level
proinflammatori
cytokin
chemokin
higher
patient
sever
diseas
die
develop
acut
respiratori
distress
syndrom
diseas
moder
sever
mild
symptom
granulocyt
colonystimul
factor
gcsf
level
higher
patient
sever
diseas
moder
mild
sever
initi
three
day
symptom
onset
level
persist
elev
cours
ill
hand
level
found
lower
sever
group
sampl
collect
within
three
day
symptom
onset
differ
significantli
sampl
collect
later
four
day
symptom
onset
anoth
studi
compar
singl
serum
sampl
collect
median
five
day
symptom
onset
highest
level
found
sever
case
level
note
similar
critic
case
noncrit
hospit
case
higher
outpati
control
high
level
proinflammatori
cytokin
may
mediat
sustain
elev
tolllik
receptor
seen
human
postmortem
lung
tissu
taken
togeth
immunodysregul
key
factor
patient
sever
diseas
degre
cytokin
activ
may
much
less
pathogen
avian
viru
sever
viru
infect
rang
asymptomat
infect
fatal
diseas
host
genet
makeup
propos
one
determin
sinc
differ
strain
inbr
mice
exhibit
variabl
suscept
infect
season
influenza
viru
understand
host
determin
influenza
viral
replic
facilit
develop
antiinfluenza
treatment
direct
host
factor
instead
viral
target
use
yeast
twohybrid
analysi
genom
wide
express
profil
human
factor
propos
involv
viralhost
interact
season
influenza
viru
broadli
divid
involv
viral
replic
involv
regul
anoth
studi
identifi
interferoninduc
transmembran
protein
critic
antivir
action
interferon
type
ii
season
influenza
virus
use
genomewid
rna
interfer
screen
mani
host
factor
shown
associ
replic
viru
signific
certain
host
factor
confirm
either
knockdown
mutant
could
produc
specif
host
factor
inhibit
factor
use
small
molecul
inhibitor
protein
includ
son
dna
bind
protein
traffick
influenza
viron
earli
infect
cdclike
kinas
splice
viral
messeng
rna
requir
late
stage
viral
replic
anoth
studi
inhibit
gene
express
use
sirna
confirm
import
gene
viral
replic
viru
includ
involv
viral
entri
postvir
entri
step
includ
transcript
regul
ha
cleavag
nuclear
traffick
mechan
inhibit
viral
cycl
unknown
australian
studi
demonstr
associ
immunoglobulin
igg
defici
sever
diseas
studi
patient
sever
infect
defin
admiss
intens
care
unit
icu
respiratori
andor
vasopressor
support
significantli
lower
level
igg
patient
diseas
moder
sever
patient
also
low
level
igg
convalesc
sera
sinc
halflif
igg
three
week
author
suggest
patient
like
underli
igg
defici
rather
low
igg
level
precipit
viru
infect
patient
underli
igg
defici
may
abl
mount
earli
innat
immun
respons
influenza
thu
predispos
sever
diseas
fatal
case
viru
infect
suffer
respiratori
failur
lung
patholog
repres
promin
find
autopsi
studi
main
patholog
featur
lung
includ
diffus
alveolar
damag
dad
necrot
bronchiol
dad
intens
alveolar
hemorrhag
similar
report
fatal
case
previou
pandem
pulmonari
arteri
microthrombi
present
case
two
seri
phenomenon
describ
patient
season
influenza
one
postul
thrombosi
may
trigger
transient
appear
anticardiolipin
antibodi
addit
lower
respiratori
tract
tracheiti
also
found
evid
secondari
bacteri
infect
seen
postmortem
case
bacteri
pathogen
includ
streptococcu
pneumonia
staphylococcu
aureu
streptococcu
pyogen
haemophilu
influenza
streptococcu
miti
coinfect
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
led
fatal
diseas
yearold
immunocompet
man
patient
area
typic
chang
bacteri
pneumonia
name
patchi
consolid
polymorph
insid
alveolar
cell
area
featur
typic
viral
pneumon
alveolar
space
necrot
debri
detach
pneumocyt
atyp
pneumocyt
mildli
enlarg
nuclei
granular
vacuol
cytoplasm
influenza
viru
infect
may
predispos
bacteri
infect
destruct
physic
barrier
expos
potenti
bind
site
bacteria
impair
mucociliari
clearanc
immunodysregul
upregul
receptor
express
bacteri
gene
encod
toxin
convers
aureu
specif
proteas
cleav
influenza
ha
may
increas
viral
replic
extrapulmonari
patholog
promin
patient
lymphoid
aggreg
myofibril
necrosi
myocardium
typic
featur
viral
myocard
found
one
case
seri
revers
cardiac
dysfunct
occur
viru
infect
case
may
myocard
hemophagocytosi
frequent
histopatholog
find
patient
sever
infect
intracellular
pathogen
evid
lymph
node
case
splenic
vein
thrombosi
found
patient
suffer
multiorgan
failur
hepat
necrosi
found
autopsi
pregnant
woman
viral
load
studi
inform
us
speed
viral
clearanc
initi
viral
load
import
predict
sever
antivir
drug
consid
cornerston
treatment
influenza
current
strain
pandem
influenza
univers
resist
amantadin
rimantadin
due
mutat
gene
remain
sensit
neuraminidas
inhibitor
includ
oseltamivir
zanamivir
peramivir
retrospect
studi
delay
treatment
oseltamivir
associ
icu
admiss
death
may
explain
faster
viral
load
reduct
patient
receiv
oseltamivir
within
two
day
symptom
onset
howev
reduct
viral
load
slow
patient
still
detect
viru
nasopharyng
aspir
five
day
treatment
regardless
time
start
oseltamivir
furthermor
oseltamivirresist
strain
emerg
worldwid
februari
oseltamivirresist
strain
report
world
health
organ
strain
contain
mutat
unrel
cluster
found
commun
hospit
oseltamivirresist
strain
may
exist
quasispeci
may
hinder
detect
resist
strain
oseltamivir
resist
may
also
emerg
patient
take
oseltamivir
postexposur
prophylaxi
treatment
intraven
zanamivir
success
old
girl
acut
lymphoblast
leukemia
anoth
yearold
woman
hodgkin
diseas
infect
oseltamivirresist
strain
viru
still
detect
day
intraven
zanamivir
respect
furthermor
one
two
case
start
high
dose
steroid
concomitantli
thu
caus
improv
still
uncertain
although
zanamivir
resist
detect
current
pandem
strain
report
season
influenza
viru
intraven
peramivir
also
avail
ic
oseltamivirresist
strain
high
unlik
use
oseltamivirresist
case
addit
neuraminidas
inhibitor
class
antivir
agent
influenza
develop
includ
adamantanamin
deriv
inosin
monophosph
imp
dehydrogenas
inhibitor
rna
polymeras
inhibitor
sirna
addit
drug
target
viru
directli
drug
alter
host
factor
also
develop
vitro
studi
shown
sialidas
fusion
protein
remov
cellsurfac
sialic
acid
residu
respiratori
epithelia
potent
antivir
effect
viru
includ
oseltamivirresist
strain
shown
standard
extract
echinacea
purpurea
activ
viru
includ
oseltamivirresist
strain
mechan
action
unclear
effect
antivir
drug
urgent
need
decreas
viral
burden
henc
may
improv
prognosi
patient
sever
diseas
viru
found
extrapulmonari
tissu
optim
antivir
agent
abl
achiev
high
concentr
tissu
oral
oseltamivir
good
absorpt
use
patient
toler
oral
feed
poor
gastrointestin
absorpt
although
zanamivir
good
antivir
activ
even
oseltamivirresist
strain
nebul
inhal
rout
would
achiev
low
system
concentr
therefor
current
avail
option
parenter
form
zanamivir
peramivir
unfortun
resist
season
viru
report
even
parenter
agent
market
import
rememb
earli
treatment
mild
case
antivir
drug
would
decreas
viral
load
rapidli
earlier
resolut
symptom
one
day
whether
earli
treatment
risk
factor
sever
diseas
prevent
progress
death
uncertain
sinc
viral
load
plateau
time
present
sever
case
efficaci
parenter
antivir
drug
remain
determin
formal
clinic
trial
patient
sever
diseas
apart
antivir
treatment
antibacteri
coverag
also
necessari
high
preval
bacteri
coinfect
empir
antibiot
abl
cover
potenti
bacteri
pathogen
especi
aureu
includ
camrsa
pneumonia
pyogen
diagnost
test
bacteri
copathogen
employ
guid
antibiot
therapi
persist
cytokin
activ
evid
patient
sever
diseas
strategi
damn
deleteri
inflammatori
respons
requir
pool
immunoglobulin
form
convalesc
plasma
hyperimmun
globulin
may
serv
antivir
immunomodulatori
function
metaanalysi
use
convalesc
plasma
influenza
pandem
lower
mortal
rate
convalesc
plasma
group
convalesc
plasma
also
shown
effect
patient
sever
infect
howev
effect
viru
infect
report
pool
immunoglobulin
also
success
two
patient
sever
diseas
igg
defici
studi
mous
model
show
monoclon
antibodi
effect
oseltamivir
treatment
season
viru
infect
hyperimmun
globulin
may
use
strategi
mathemat
model
shown
passiv
immunotherapi
feasibl
option
even
low
percentag
donor
corticosteroid
matter
debat
studi
involv
patient
icu
report
success
use
corticosteroid
suggest
low
dose
steroid
help
sever
case
compens
rel
adren
insuffici
addit
celecoxib
mesalazin
antivir
drug
improv
surviv
mice
potenti
immunomodul
includ
fibrat
statin
howev
agent
test
set
pandem
influenza
await
studi
establish
efficaci
advanc
medic
scienc
technolog
knowledg
regard
viru
expand
unpreced
pace
character
viral
host
determin
sever
diseas
would
import
understand
pathogenesi
form
basi
formul
scientif
sound
strategi
clinic
manag
